{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:23:23Z","timestamp":1785363803067,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001822","name":"\u00d6sterreichische Akademie der Wissenschaften","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jad.2025.120466","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:03:05Z","timestamp":1760425385000},"page":"120466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"PA","title":["Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis"],"prefix":"10.1016","volume":"394","author":[{"given":"Leo R.","family":"Silberbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Eggerstorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Michenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Reichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stimpfl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vanicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Naderi-Heiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Lanzenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Gryglewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.120466_bb0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0010","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jad.2018.02.056","article-title":"Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial","volume":"235","author":"Arabzadeh","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120466_bb0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","article-title":"Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice","volume":"20","author":"Bartova","year":"2019","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00000542-199801000-00015","article-title":"Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations","volume":"88","author":"Bowdle","year":"1998","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jad.2025.120466_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma. Stress."},{"key":"10.1016\/j.jad.2025.120466_bb0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41398-021-01230-z","article-title":"Low dose oral ketamine treatment in chronic suicidality: an open-label pilot study","volume":"11","author":"Can","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0040","first-page":"269","article-title":"Relationship between dissociation and antidepressant effects of esketamine nasal spray in patients with treatment-resistant depression","volume":"25","author":"Chen","year":"2022","journal-title":"Int. J. Neuropharmacol."},{"key":"10.1016\/j.jad.2025.120466_bb0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpsychires.2024.03.002","article-title":"Oral prolonged-release ketamine in treatment-resistant depression - a double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - clinical and safety results","volume":"173","author":"Colla","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2025.120466_bb0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1192\/bjp.2018.196","article-title":"Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"214","author":"Domany","year":"2019","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.jad.2025.120466_bb0055","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jad.2022.01.018","article-title":"Oral ketamine reduces the experience of stress in people with chronic suicidality","volume":"300","author":"Dutton","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120466_bb0060","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-023-06480-x","article-title":"Oral ketamine may offer a solution to the ketamine conundrum","author":"Dutton","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.120466_bb0065","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-015-1826-y","article-title":"Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing","volume":"71","author":"Fanta","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.120466_bb0070","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","author":"Fava","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0075","first-page":"616","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropharmacol."},{"key":"10.1016\/j.jad.2025.120466_bb0080","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00228-020-03047-z","article-title":"Influence of formulation and route of administration on ketamine\u2019s safety and tolerability: systematic review","volume":"77","author":"Glue","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.120466_bb0085","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/s41591-024-03063-x","article-title":"Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial","volume":"30","author":"Glue","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jad.2025.120466_bb0090","article-title":"Functional recovery in major depressive disorder: focus on early optimized treatment","volume":"18","author":"Habert","year":"2016","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.jad.2025.120466_bb0095","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/jpm.2012.0617","article-title":"Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial","volume":"16","author":"Irwin","year":"2013","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.jad.2025.120466_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2016.05.076","article-title":"Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial","volume":"204","author":"Jafarinia","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120466_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.25531","article-title":"Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis","volume":"4","author":"Jones","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jad.2025.120466_bb0115","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/JCP.0000000000001289","article-title":"Comparison of rapid antidepressant and antisuicidal effects of intramuscular ketamine, oral ketamine, and electroconvulsive therapy in patients with major depressive disorder: a pilot study","volume":"40","author":"Kheirabadi","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.jad.2025.120466_bb0120","article-title":"High-dose versus low-dose oral ketamine on control and relapse of treatment-resistant depression: a randomized, double-blinded clinical trial","volume":"17","author":"KheirAbadi","year":"2023","journal-title":"Iran. J. Psychiatry Behav. Sci."},{"key":"10.1016\/j.jad.2025.120466_bb0125","article-title":"Trial of ketamine masked by surgical anesthesia in depressed patients","author":"Lii","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jad.2025.120466_bb0130","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2025.120466_bb0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/02698811221140011","article-title":"A unified model of ketamine's dissociative and psychedelic properties","volume":"37","author":"Marguilho","year":"2023","journal-title":"J. Psychopharmacol. (Oxf. Engl.)"},{"key":"10.1016\/j.jad.2025.120466_bb0140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0145","first-page":"1","article-title":"Oral ketamine for depression: an updated systematic review","author":"Meshkat","year":"2023","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1037\/1082-989X.7.1.105","article-title":"Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs","volume":"7","author":"Morris","year":"2002","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.jad.2025.120466_bb0155","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0160","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euroneuro.2021.01.005","article-title":"Comparative effects of (S)-ketamine and racemic (R\/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers","volume":"44","author":"Passie","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.120466_bb0165","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","article-title":"Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy","volume":"55","author":"Peltoniemi","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jad.2025.120466_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0175","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ps.201900625","article-title":"Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States","volume":"71","author":"Ross","year":"2020","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jad.2025.120466_bb0180","article-title":"Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials","author":"Saelens","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.120466_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2025.104413","article-title":"Oral ketamine for rapid reduction of suicidal ideation in major depressive disorder: a midazolam-controlled randomized clinical trial","volume":"106","author":"Seraj","year":"2025","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jad.2025.120466_bb0190","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/JCP.0000000000001238","article-title":"Oral ketamine as a treatment option in patients with treatment resistant depression and comorbid arterial hypertension","volume":"40","author":"Silberbauer","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120466_bb0195","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41380-024-02478-9","article-title":"Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension","volume":"29","author":"Smith-Apeldoorn","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jad.2025.120466_bb0205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/acps.13260","article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression","volume":"143","author":"Turkoz","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2025.120466_bb0210","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JCP.0000000000000960","article-title":"Efficacy and safety of a rapid intravenous injection of ketamine 0.5 mg\/kg in treatment-resistant major depression: an open 4-week longitudinal study","volume":"38","author":"Vidal","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2025.120466_bb2210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.jad.2025.120466_bb0215","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41386-019-0317-8","article-title":"Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant","volume":"44","author":"Wilkinson","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.120466_bb0220","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0225","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jad.2025.120466_bb0230","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0235","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.120466_bb0240","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725019081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725019081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:56:48Z","timestamp":1780822608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725019081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":48,"alternative-id":["S0165032725019081"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.120466","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.120466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120466"}}